Theoharis Theoharides

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
Theoharis Theoharides.png

Theoharis C. Theoharides, MS, MPhil, PhD, MD, is a Professor of Pharmacology and Internal Medicine and the Director of the Molecular Immunopharmacology and Drug Discovery Laboratory at Tufts University School of Medicine, Boston, Massachusetts, US. His lab, the Theoharis Theoharides Lab, at Sackler School of Graduate Biomedical Sciences, investigates the mechanism of selective secretion of cytokines and other pro-inflammatory molecules from mast cells.[1]

Dr. Theoharides's special interests include mechanisms of inflammation, neuroimmunoendocrine disorders, mast cell activation disorders, autism, and Ehlers-Danlos syndrome.

Notable studies[edit | edit source]

Dr. Theoharides has published over 270 research papers and 2 textbooks of Pharmacology.[2]

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Theoharis Theoharides". Sackler School of Graduate Biomedical Sciences. April 9, 2018. Retrieved August 16, 2018.
  2. "President Theoharis C. Theoharides, MS, PhD, MD, FAAAAI". Retrieved March 18, 2021.
  3. Vasiadi, Magdalini; Newman, Jennifer; Theoharides, Theoharis C (October 31, 2014). "Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to chronic fatigue syndrome". Journal of Neuroinflammation. 11 (1). doi:10.1186/s12974-014-0168-5. ISSN 1742-2094. PMID 25359293.
  4. Hatziagelaki, Erifili; Adamaki, Maria; Tsilioni, Irene; Dimitriadis, George; Theoharides, Theoharis C. (January 1, 2018). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Metabolic Disease or Disturbed Homeostasis?". Journal of Pharmacology and Experimental Therapeutics: jpet.118.250845. doi:10.1124/jpet.118.250845. ISSN 0022-3565. PMID 30076265.
  5. Theoharides, Theoharis C.; Tsilioni, Irene (November 19, 2018). "Tetramethoxyluteolin for the treatment of neurodegenerative diseases". Current Topics in Medicinal Chemistry. 18. doi:10.2174/1568026617666181119154247. ISSN 1568-0266.
  6. "Dr. T. C. Theoharides presents "Mast Cell Disorders"". YouTube. Retrieved March 18, 2021.
  7. "Invest in ME Research - IIMEC13 Invest in ME Research ME Conference 2018". Invest in ME Research. Retrieved August 16, 2018.
  8. "Curriculum Vitae - Theoharis C. Theoharides" (PDF). Retrieved March 18, 2021.
  9. "Dr T C Theoharides, MD Ph.D., - Mast Cells, Autism, Inflammation". Retrieved August 16, 2018.
  10. "Theoharis Theoharides". Sackler School of Graduate Biomedical Sciences. April 9, 2018. Retrieved August 16, 2018.

serum The clear yellowish fluid that remains from blood plasma after clotting factors have been removed by clot formation. (Blood plasma is simply blood that has had its blood cells removed.)

myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.